Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025)
Canopy Growth's (CGC) quarterly Income from Non-Controlling Interests came in at $94.1 million in Q1 2025, up 953.0% quarter-over-quarter from -$11.0 million in Q3 2023.
Canopy Growth (CGC) Income from Non-Controlling Interests (2019 - 2025) Analysis & Trends
Canopy Growth has disclosed Income from Non-Controlling Interests across 6 years of filings, most recently posting $94.1 million for Q1 2025.
- Income from Non-Controlling Interests for Q1 2025 came in at $94.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $83.1 million (up 701.23% YoY), and the FY2024 annual result was -$13.7 million, down 879.79% from the prior year.
- Income from Non-Controlling Interests came in at $94.1 million for Q1 2025 at Canopy Growth, up from -$11.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $94.1 million in Q1 2025 to a low of -$11.0 million in Q3 2023.
- The 4-year median for Income from Non-Controlling Interests is -$1.5 million (2021), against an average of $12.7 million.
- Across the five-year window, Income from Non-Controlling Interests soared 477.26% in 2021 and slumped 1015.95% in 2023, its largest moves.
- Canopy Growth's Income from Non-Controlling Interests stood at -$5.2 million in 2021, then soared by 92.34% to -$399293.0 in 2022, then plunged by 2662.21% to -$11.0 million in 2023, then soared by 953.0% to $94.1 million in 2025.
- The last three Income from Non-Controlling Interests figures came in at $94.1 million (Q1 2025), -$11.0 million (Q3 2023), and -$2.8 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Canopy Growth | 11.27 Mn | -137.42 Mn | 15.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 94.08 Mn |
| Sep 30, 2023 | -11.03 Mn |
| Jun 30, 2023 | -2.78 Mn |
| Mar 31, 2023 | 14.88 Mn |
| Dec 31, 2022 | -399,292.99 |
| Sep 30, 2022 | -988,335.91 |
| Jun 30, 2022 | -4.16 Mn |
| Mar 31, 2022 | 7.84 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -4.19 Mn |
| Jun 30, 2021 | -2.00 Mn |
| Mar 31, 2021 | 65.80 Mn |
| Dec 31, 2020 | 57.63 Mn |
| Sep 30, 2020 | -48.40 Mn |
| Jun 30, 2020 | -14.29 Mn |
| Mar 31, 2020 | -17.44 Mn |
| Dec 31, 2019 | -13.85 Mn |
| Sep 30, 2019 | -12.33 Mn |
| Jun 30, 2019 | -6.12 Mn |